Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study.

Background: Clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 (PD-1) remain unknown.

Objective: To better characterize the occurrence of vitiligo in patients receiving anti-PD-1.

Methods: The present single-center ambispective cohort study included patients with melanoma treated with anti-PD-1.